Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

David Sallman, MD

David Sallman: Early Results of 5F9 in AML and MDS

David Sallman, MD, discusses the initial results seen in a phase Ib trial of the anti-CD47 antibody 5F9 in patients with acute myeloid leukemia...
On location

CX-01 Combination Associated With High Response Rate in Older Patients With AML

Treatment with CX-01 and standard chemotherapy induced high response rates – including complete responses (CRs) – in older patients newly diagnosed with acute myeloid...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...

FDA’s ODAC Recommends Against Approval of Quizartinib for AML

In an 8-to-3 vote, the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending approval of quizartinib for patients...

Japan Sets $306,000 Price for Tisagenlecleucel

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was approved for use in Japan in March 2019, and a government panel recently set the...

FDA Expands Ivosidenib’s Indication to Newly Diagnosed AML

On May 2, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the IDH1 inhibitor ivosidenib to include the treatment of...

Medicare Payments for CAR T-Cell Therapy May Be on the Rise

Medicare beneficiaries with relapsed or refractory leukemia and lymphoma may soon have another treatment option. At least, that’s the hope of officials at the...

International Partnerships Lead to Strides in Pediatric Leukemia in El Salvador

Although acute lymphocytic leukemia (ALL) is relatively rare, it is the most common cancer diagnosed in children, representing approximately one-quarter of cancers diagnosed in...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including the first treatment...

New Treatment Options Lead to New Questions in Acute Myeloid Leukemia

For the past 40 years, the standard remission induction treatment for patients with newly diagnosed acute myeloid leukemia (AML) who are candidates for intensive...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.